These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 36825076)

  • 1. Empagliflozin as an adjunctive therapy for type 1 diabetes.
    MacIsaac RJ; Lee MH; McAuley SA; Ward GM; O'Neal DN
    Ann Transl Med; 2018 Dec; 6(Suppl 2):S134. PubMed ID: 30740455
    [No Abstract]   [Full Text] [Related]  

  • 2. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
    Fu EL; Patorno E; Everett BM; Vaduganathan M; Solomon SD; Levin R; Schneeweiss S; Desai RJ
    Eur Heart J; 2023 Jun; 44(24):2216-2230. PubMed ID: 37259575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
    JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece.
    Ghetti G; Pradelli L; Papageorgiou G; Karpouzos G; Arikan Y
    Clinicoecon Outcomes Res; 2023; 15():97-109. PubMed ID: 36825076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.
    Ramos M; Foos V; Ustyugova A; Hau N; Gandhi P; Lamotte M
    Diabetes Ther; 2019 Dec; 10(6):2153-2167. PubMed ID: 31602601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
    Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M
    Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
    Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
    Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
    Eliasson B; Ericsson Å; Fridhammar A; Nilsson A; Persson S; Chubb B
    Pharmacoecon Open; 2022 May; 6(3):343-354. PubMed ID: 35064550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
    Patorno E; Pawar A; Wexler DJ; Glynn RJ; Bessette LG; Paik JM; Najafzadeh M; Brodovicz KG; Déruaz-Luyet A; Schneeweiss S
    Diabetes Obes Metab; 2022 Mar; 24(3):442-454. PubMed ID: 34729891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.
    Ramos M; Men P; Wang X; Ustyugova A; Lamotte M
    Cost Eff Resour Alloc; 2021 Aug; 19(1):46. PubMed ID: 34348729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
    Malkin SJP; Hunt B; Huisman EL; Grand TS; Chubb B
    Diabetes Res Clin Pract; 2021 May; 175():108759. PubMed ID: 33744377
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.